Published in J Biol Chem on March 26, 2008
Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz (2009) 1.41
Conformational plasticity and structure/function relationships in cytochromes P450. Antioxid Redox Signal (2010) 1.40
Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis (2010) 1.30
Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl Trop Dis (2009) 1.29
The Mycobacterium tuberculosis cytochrome P450 system. Arch Biochem Biophys (2009) 1.16
Heterologous expression of mutated eburicol 14alpha-demethylase (CYP51) proteins of Mycosphaerella graminicola to assess effects on azole fungicide sensitivity and intrinsic protein function. Appl Environ Microbiol (2010) 1.05
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrob Agents Chemother (2008) 1.01
Three-dimensional model of lanosterol 14 alpha-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding. Antimicrob Agents Chemother (2009) 0.96
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae. Antimicrob Agents Chemother (2008) 0.88
Drug Strategies Targeting CYP51 in Neglected Tropical Diseases. Chem Rev (2014) 0.86
Identification of small-molecule scaffolds for p450 inhibitors. Curr Protoc Microbiol (2010) 0.81
The use of small molecule high-throughput screening to identify inhibitors of the proteinase 3-NB1 interaction. Clin Exp Immunol (2010) 0.80
Expanding the binding envelope of CYP51 inhibitors targeting Trypanosoma cruzi with 4-aminopyridyl-based sulfonamide derivatives. Chembiochem (2014) 0.79
Ligand tunnels in T. brucei and human CYP51: Insights for parasite-specific drug design. Biochim Biophys Acta (2015) 0.78
Evolutionary trace analysis of CYP51 family: implication for site-directed mutagenesis and novel antifungal drug design. J Mol Model (2009) 0.77
Spin equilibrium and O₂-binding kinetics of Mycobacterium tuberculosis CYP51 with mutations in the histidine-threonine dyad. J Inorg Biochem (2014) 0.76
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
VMD: visual molecular dynamics. J Mol Graph (1996) 117.02
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 60.62
THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. J Biol Chem (1964) 8.70
Current and emerging azole antifungal agents. Clin Microbiol Rev (1999) 5.70
Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother (1998) 4.93
Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2001) 4.05
A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc Natl Acad Sci U S A (2007) 4.04
Essential role for cholesterol in entry of mycobacteria into macrophages. Science (2000) 3.36
Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (1999) 3.19
Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol (2008) 2.97
Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci U S A (2001) 2.90
The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci (2000) 2.42
Systemic absorption of sunscreen after topical application. Lancet (1997) 2.36
Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother (2004) 2.20
Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol (2003) 1.87
CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase. J Biol Chem (2005) 1.83
Cure of short- and long-term experimental Chagas' disease using D0870. Science (1996) 1.75
A different function for a member of an ancient and highly conserved cytochrome P450 family: from essential sterols to plant defense. Proc Natl Acad Sci U S A (2006) 1.71
Microbial degradation of dibenzofuran, fluorene, and dibenzo-p-dioxin by Staphylococcus auriculans DBF63. Appl Environ Microbiol (1993) 1.66
Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem (2007) 1.62
The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem (2005) 1.60
Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol (2006) 1.60
Characterization and catalytic properties of the sterol 14alpha-demethylase from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (1999) 1.60
Actions of a versatile fluorene-degrading bacterial isolate on polycyclic aromatic compounds. Appl Environ Microbiol (1995) 1.55
Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother (2006) 1.46
Pestalone, a new antibiotic produced by a marine fungus in response to bacterial challenge. J Nat Prod (2001) 1.40
Antifungal and antimycobacterial activity of new imidazole and triazole derivatives. A combined experimental and computational approach. J Antimicrob Chemother (2006) 1.36
Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett (1999) 1.31
Substrate recognition sites in 14alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. J Inorg Biochem (2001) 1.25
Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother (2003) 1.25
Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob Agents Chemother (1999) 1.21
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography. Antimicrob Agents Chemother (2007) 1.20
Estrogenic and antiandrogenic activities of 17 benzophenone derivatives used as UV stabilizers and sunscreens. Toxicol Appl Pharmacol (2005) 1.13
1,4-Benzothiazine and 1,4-benzoxazine imidazole derivatives with antifungal activity: a docking study. Bioorg Med Chem (2002) 1.11
Regio- and stereospecific oxidation of fluorene, dibenzofuran, and dibenzothiophene by naphthalene dioxygenase from Pseudomonas sp. strain NCIB 9816-4. Appl Environ Microbiol (1996) 1.11
Molecular characterization of cytochrome P450 genes in the polycyclic aromatic hydrocarbon degrading Mycobacterium vanbaalenii PYR-1. Appl Microbiol Biotechnol (2005) 1.11
Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology. J Lipid Res (2004) 1.09
Mechanistic studies of lanosterol C-32 demethylation. Conditions which promote oxysterol intermediate accumulation during the demethylation process. J Biol Chem (1986) 1.07
Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems. Arch Biochem Biophys (2007) 1.04
Synthesis and antifungal activities of novel 2-aminotetralin derivatives. J Med Chem (2007) 1.03
Design, synthesis, and microbiological evaluation of new Candida albicans CYP51 inhibitors. J Med Chem (2005) 1.03
CYP51-like gene of Mycobacterium tuberculosis actually encodes a P450 similar to eukaryotic CYP51. J Biochem (1998) 1.03
Absorption of sunscreens and other compounds through human skin in vivo: derivation of a method to predict maximum fluxes. Pharm Res (1995) 1.00
New metabolites in the degradation of fluorene by Arthrobacter sp. strain F101. Appl Environ Microbiol (1997) 0.99
Fluorene degradation by Sphingomonas sp. LB126 proceeds through protocatechuic acid: a genetic analysis. Res Microbiol (2001) 0.99
Absorption of sunscreens across human skin: an evaluation of commercial products for children and adults. Br J Clin Pharmacol (1999) 0.99
Recent progress in the CYP51 research focusing on its unique evolutionary and functional characteristics as a diversozyme P450. Front Biosci (2005) 0.98
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking. J Med Chem (2006) 0.98
Structural and evolutionary studies on sterol 14-demethylase P450 (CYP51), the most conserved P450 monooxygenase: II. Evolutionary analysis of protein and gene structures. J Biochem (1997) 0.96
Metabolism of fluoranthene by Mycobacterium sp. strain AP1. Appl Microbiol Biotechnol (2005) 0.90
Homology modeling of lanosterol 14alpha-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate Interactions. J Biomol Struct Dyn (2004) 0.90
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos (2006) 0.89
Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. J Med Chem (2003) 0.88
Expression and homology modeling of sterol 14alpha-demethylase from Penicillium digitatum. FEMS Microbiol Lett (2007) 0.87
Conversion of polycyclic aromatic hydrocarbons by Sphingomonas sp. VKM B-2434. Biodegradation (2007) 0.87
Isolation and identification of mycobacteria from soils at an illegal dumping site and landfills in Japan. Microbiol Immunol (2006) 0.87
Molecular design of two sterol 14alpha-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole. J Comput Aided Mol Des (2005) 0.86
Metabolism of fluoranthene by mycobacterial strains isolated by their ability to grow in fluoranthene or pyrene. J Ind Microbiol Biotechnol (2005) 0.84
Modeling and interactions of Aspergillus fumigatus lanosterol 14-alpha demethylase 'A' with azole antifungals. Bioorg Med Chem (2004) 0.83
Binding structures and potencies of oxidosqualene cyclase inhibitors with the homologous squalene-hopene cyclase. J Med Chem (2003) 0.83
Microscopy reveals disease control through novel effects on fungal development: a case study with an early-generation benzophenone fungicide. Pest Manag Sci (2006) 0.81
Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae. Antimicrob Agents Chemother (2006) 0.80
Metrafenone: studies on the mode of action of a novel cereal powdery mildew fungicide. Pest Manag Sci (2006) 0.80
Design, synthesis, and antifungal activities in vitro of novel tetrahydroisoquinoline compounds based on the structure of lanosterol 14alpha-demethylase (CYP51) of fungi. Bioorg Med Chem Lett (2006) 0.79
Nonsteroidal benzophenone-containing analogues of cholesterol. J Org Chem (2006) 0.76
Design, synthesis, and antifungal activities of novel 1H-triazole derivatives based on the structure of the active site of fungal lanosterol 14 alpha-demethylase (CYP51). Chem Biodivers (2007) 0.76
Iron and microbial infection. Nat Rev Microbiol (2004) 4.53
Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity (2007) 3.61
Malnutrition and infection: complex mechanisms and global impacts. PLoS Med (2007) 3.40
Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med (2003) 3.24
Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest (2005) 3.19
New insights into the function of granulomas in human tuberculosis. J Pathol (2006) 2.96
Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog (2012) 2.87
Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet (2012) 2.83
Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) (2007) 2.69
Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A (2007) 2.62
Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity (2006) 2.61
Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci U S A (2004) 2.49
Cutting Edge: Regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J Immunol (2007) 2.43
Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A (2012) 2.42
Identification of LRRC8 heteromers as an essential component of the volume-regulated anion channel VRAC. Science (2014) 2.42
Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis. Infect Immun (2006) 2.27
Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. J Exp Med (2002) 2.20
Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol (2004) 2.11
Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity (2010) 2.09
Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev (2012) 2.07
The Mycobacterium tuberculosis regulatory network and hypoxia. Nature (2013) 2.04
Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One (2012) 1.97
Correction of the iron overload defect in beta-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med (2002) 1.93
Saposin C is required for lipid presentation by human CD1b. Nat Immunol (2004) 1.88
Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. J Immunol (2003) 1.82
Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur J Immunol (2006) 1.81
MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci U S A (2002) 1.79
Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif. Int Immunol (2004) 1.76
Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during Salmonella typhimurium infection. Immunity (2010) 1.75
Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. Eur J Immunol (2003) 1.74
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) (2005) 1.73
Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS One (2011) 1.73
The adaptor molecule CARD9 is essential for tuberculosis control. J Exp Med (2010) 1.70
Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strain. Cell Host Microbe (2008) 1.69
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 1.69
Notch signaling is activated by TLR stimulation and regulates macrophage functions. Eur J Immunol (2008) 1.68
Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol (2009) 1.67
T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect Immun (2003) 1.65
Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J Infect Dis (2003) 1.60
Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. J Infect Dis (2006) 1.59
The structural basis for substrate anchoring, active site selectivity, and product formation by P450 PikC from Streptomyces venezuelae. J Biol Chem (2006) 1.59
Comparative proteome analysis of culture supernatant proteins from virulent Mycobacterium tuberculosis H37Rv and attenuated M. bovis BCG Copenhagen. Electrophoresis (2003) 1.57
Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. Am J Respir Crit Care Med (2014) 1.54
Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of Streptomyces coelicolor A3(2) cytochrome P450 158A2. J Biol Chem (2005) 1.52
Mycobacterium tuberculosis CYP125A1, a steroid C27 monooxygenase that detoxifies intracellularly generated cholest-4-en-3-one. Mol Microbiol (2010) 1.49
Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency. Nat Biotechnol (2005) 1.47
Mycobacterium tuberculosis-specific CD4+, IFNgamma+, and TNFalpha+ multifunctional memory T cells coexpress GM-CSF. Cytokine (2008) 1.46
The RD1 proteins of Mycobacterium tuberculosis: expression in Mycobacterium smegmatis and biochemical characterization. Microbes Infect (2003) 1.45
Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest (2006) 1.45
The Mtb proteome library: a resource of assays to quantify the complete proteome of Mycobacterium tuberculosis. Cell Host Microbe (2013) 1.44
Identification of T-cell antigens specific for latent mycobacterium tuberculosis infection. PLoS One (2009) 1.40
Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. J Infect Dis (2005) 1.40
Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc Natl Acad Sci U S A (2005) 1.38
For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunol Rev (2011) 1.34
The IFN-inducible Golgi- and endoplasmic reticulum- associated 47-kDa GTPase IIGP is transiently expressed during listeriosis. J Immunol (2002) 1.34
Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs. J Biol Chem (2007) 1.33
The cytochrome P450 complement (CYPome) of Streptomyces coelicolor A3(2). J Biol Chem (2002) 1.32
CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction. Proteomics (2004) 1.32
MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics (2003) 1.31
Characterization of the murine T-lymphocyte response to Salmonella enterica serovar Typhimurium infection. Infect Immun (2002) 1.30
Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis (2010) 1.30
Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis (2011) 1.30
Biomarker discovery in heterogeneous tissue samples -taking the in-silico deconfounding approach. BMC Bioinformatics (2010) 1.30
Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect Immun (2004) 1.30
Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl Trop Dis (2009) 1.29
Complementary analysis of the Mycobacterium tuberculosis proteome by two-dimensional electrophoresis and isotope-coded affinity tag technology. Mol Cell Proteomics (2003) 1.29
Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology (2008) 1.26
Modified immunohistological staining allows detection of Ziehl-Neelsen-negative Mycobacterium tuberculosis organisms and their precise localization in human tissue. J Pathol (2005) 1.26
Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide. Cell Microbiol (2008) 1.26
Apoptosis paves the detour path for CD8 T cell activation against intracellular bacteria. Cell Microbiol (2004) 1.26
Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect Immun (2008) 1.26
The quest for biomarkers in tuberculosis. Drug Discov Today (2009) 1.25
CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest (2014) 1.24
Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Miycobacterium bovis bacille Calmette-Guérin induce equal protection. J Infect Dis (2004) 1.23
IIGP, a member of the IFN inducible and microbial defense mediating 47 kDa GTPase family, interacts with the microtubule binding protein hook3. J Cell Sci (2004) 1.23
Progress in tuberculosis vaccine development. Curr Opin Immunol (2006) 1.23
MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest (2013) 1.23
A role for IL-18 in protective immunity against Mycobacterium tuberculosis. Eur J Immunol (2010) 1.22
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob Agents Chemother (2010) 1.22
Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A (2012) 1.22
Organ-specific CD4+ T cell response during Listeria monocytogenes infection. J Immunol (2002) 1.22
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography. Antimicrob Agents Chemother (2007) 1.20
Ten years of the Global Alliance for Vaccines and Immunization: challenges and progress. Nat Immunol (2010) 1.19
Engineering and analysis of a self-sufficient biosynthetic cytochrome P450 PikC fused to the RhFRED reductase domain. J Am Chem Soc (2007) 1.18
Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc Natl Acad Sci U S A (2002) 1.18
A second FMN binding site in yeast NADPH-cytochrome P450 reductase suggests a mechanism of electron transfer by diflavin reductases. Structure (2006) 1.18
Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis. Eur J Immunol (2011) 1.18
Novel tuberculosis vaccines on the horizon. Curr Opin Immunol (2010) 1.17
Mini-review: regulatory T cells and infection: suppression revisited. Eur J Immunol (2004) 1.17
Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine (2013) 1.17
Liver NKT cells: an account of heterogeneity. Trends Immunol (2003) 1.16
A nutritive view on the host-pathogen interplay. Trends Microbiol (2005) 1.15
Neutrophilia in LFA-1-deficient mice confers resistance to listeriosis: possible contribution of granulocyte-colony-stimulating factor and IL-17. J Immunol (2003) 1.15
Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur J Immunol (2014) 1.15
Differential requirements for the chemokine receptor CCR7 in T cell activation during Listeria monocytogenes infection. J Exp Med (2005) 1.15
Critical role of NK cells rather than V alpha 14(+)NKT cells in lipopolysaccharide-induced lethal shock in mice. J Immunol (2002) 1.14